• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human LILRB1/CD85j protein (rFc Tag)(HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg3701

Validation Data Gallery

  • Purity of Recombinant Human LILRB1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Human LILRB1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

  • The purity of Human LILRB1/CD85j was greater than 90% as determined by SEC-HPLC.

    The purity of Human LILRB1/CD85j was greater than 90% as determined by SEC-HPLC.

Product Information

Purity >90 %, SDS-PAGE
>90 %, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Human LILRB1 protein Gly24-His458 (Accession# Q8NHL6) with a rabbit IgG Fc tag at the C-terminus.
GeneID 10859
Accession Q8NHL6
PredictedSize 73.5 kDa
SDS-PAGE 80-100 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

LILRB1 (Leukocyte Immunoglobulin-like Receptor B1), also known as CD85j, ILT, and MIR7, is a member of the immunoglobulin superfamily and is expressed in a wide variety of immune cells, including natural killer (NK) cells, monocytes, macrophages, and dendritic cells. LILRB1 acts as an immunosuppressive receptor functions and is involved in immunomodulation and regulation of immune response. Recently, HLA class I expression was shown to protect cancer cells from macrophage phagocytosis by interacting with LILRB1, making LILRB1 also a phagocytic checkpoint. LILRB1 is also a promising therapeutic target for patients with multiple myeloma.

References:

1. Zeller T, et al. (2023). Front Immunol. 14:1240275.                                                   
2. Hu Z, et al. (2024). Front Immunol. 15:1421092.                                                         
3. Xian M, et al. (2024). Nat Commun. 15(1):5767.